Hemab Therapeutics (COAG) Stock Price, News & Analysis

Company Overview

Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders, with a focus on conditions that have limited treatment options. Its research centers on therapies intended to help restore or regulate blood clotting.

The company’s lead candidate, HMB-001, is an investigational bispecific antibody being developed for Glanzmann thrombasthenia, a rare inherited bleeding disorder. Hemab is also advancing research into additional disorders affecting hemostasis, the process that helps the body control bleeding.

Hemab was founded in 2020 and operates in the United States and Denmark. The company is led by CEO Thomas Collins.

Key Stats

• Today's Range: $38.44 to $41.27
• 50-Day Range: $28.37 to $49.02
• 52-Week Range: $23.00 to $55.42
• Volume: 401,088 shs
• Average Volume: 512,316 shs
• Market Capitalization: $1.91 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Moderate Buy

Hemab Therapeutics Stock Analysis - MarketRank™

Hemab Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 486th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Hemab Therapeutics has a consensus price target of $56.00, representing about 37.1% upside from its current price of $40.86.

Amount of Analyst Coverage

Hemab Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hemab Therapeutics are expected to grow in the coming year, from ($3.23) to ($2.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hemab Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hemab Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hemab Therapeutics has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.08% of the float of Hemab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hemab Therapeutics has a short interest ratio ("days to cover") of 7.31.

Change versus previous month

Short interest in Hemab Therapeutics has recently increased by 4.56%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hemab Therapeutics does not currently pay a dividend.

Dividend Growth

Hemab Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.05

News Sentiment

Hemab Therapeutics has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Hemab Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for COAG on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hemab Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hemab Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/15/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• 9th Annual Evercore ISI HealthCONx Conference: 12/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:COAG
• CIK: 2114044
• Web: www.hemab.com
• Phone: (452) 138-7627
• Fax: N/A
• Employees: 59
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Hemab Therapeutics: $56.00
• High Price Target: $70.00
• Low Price Target: $36.00
• Potential Upside/Downside: +37.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.86
• Quick Ratio: 35.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.19 per share
• Price / Book: 4.45

Miscellaneous

• Outstanding Shares: 46,730,000
• Free Float: N/A
• Market Cap: $1.91 billion
• Optionable: N/A
• Beta: N/A